In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A

Executive Summary

Pfizer's acquisition of privately-held Angiosyn is basically a milestones-and-royalty-based licensing deal for the biotech's preclinical non-VEGF targeting AMD candidate. Angiosyn was designed for early M&A, much like most medical device firms of the past ten years, and this risk-sharing agreement with Pfizer may imply a new, leaner model for biotech company building.
Advertisement

Related Content

A Look Back At 2010: In Search Of New Biopharma Models
Reviewing 2005: The Top Biopharma Stories
Investing in French Biotech--When It's Not Too French
The Buzz at JP Morgan--Biopharma: New Models Wanted
Investing in French Biotech--When It's Not Too French
Why Early-Stage Dealmaking is Hot
Why Early-Stage Dealmaking is Hot
Biotech's New Breed of IPOs
Novartis and Idenix Pursue Interdependent Growth
Novartis and Idenix Pursue Interdependent Growth

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel